Recombinant Protein CDMOs — Ranked by Signal Score · 2026
Recombinant Proteins manufacturers on CDMO Signal: 14 listed, 14 with a Signal Score. Together they have 51 FDA inspections on file (including 13 NAI, 36 VAI and 2 OAI), 2 FDA warning letters and 147 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
Recombinant Proteins CDMOs with the most regulatory evidence on file
Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.
Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 13 NAI (no action), 36 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Denmark (52), United States (38), Germany (33), UNITED KINGDOM (20), UNITED STATES (9).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 2 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 3 |
KB
|
84.1 | 98.5 | 2 insp · 1 GMP | 2026-04-01 · VAI | Limited | — |
| 4 |
WK
Jena, DE · Amsterdam, NL · San Diego, CA
|
82.9 | 100.0 | 1 insp · 13 GMP | 2023-12-07 · VAI | — | — |
| 5 |
RB
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | None on file | — | — |
| 6 |
NW
|
80.8 | 100.0 | 0 insp · 8 GMP | None on file | Available | — |
| 7 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 8 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 9 |
Oklahoma City, OK
|
78.6 | 98.2 | 1 insp · 0 GMP | 2026-06-17 · VAI | Available | — |
| 10 |
RB
|
77.8 | 99.2 | 2 insp · 2 GMP | 2025-01-17 · VAI | — | — |
| 11 |
|
76.1 | 77.3 | 24 insp · 39 GMP | 2026-05-22 · VAI Warning letter 2025-11-20 |
— | — |
| 12 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |
| 13 |
SB
|
61.5 | — | — | None on file | Available | — |
| 14 |
BN
Fremont, CA
|
59.0 | — | — | None on file | — | — |